Competency profile of locally manufactured clopidogrel lowplat and foreign manufactured clopidogrel plavix in patients of suspected ischemic heart disease [CLAP-IHD]
JPMA-Journal of Pakistan Medical Association. 2005; 55 (10): 443-448
in English
| IMEMR
| ID: emr-72609
ABSTRACT
The primary objective of this study was to test the hypothesis that the antiplatelet effects of loading dose of locally manufactured clopidogrel Lowplat referred as drug [B] 600 mg [8 tablets] given once is comparable to the antiplatelet effects of loading dose of foreign manufactured clopidogrel Plavix referred as drug [A] 600 mg [8 tablets] given once in patients with suspected ischemic heart disease. This was a double blind, randomized, cross over, study, to compare the safety and efficacy of study drug [B] versus [A] in adult subjects suffering from suspected ischemic heart disease presented at National Institute of Cardiovascular Disease [NICVD], Karachi. Mean platelet aggregation inhibition by drug [B] was 60.7% [p<0.001], while with drug [A] it was 57.8% [p<0.001], using 20 micro mol/L ADP, which is statistically significant and comparable. Clopidogrel 600 mg as loading dose was well tolerated. Both drugs were equally effective in reducing the platelet aggregation. CLAP-IHD confirmed that drug [B] and [A] are equally effective and comparable antithrombotics in Pakistani population. The cost benefit of drug [B] should be made beneficial to the patients
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Platelet Aggregation Inhibitors
/
Technology, Pharmaceutical
/
Myocardial Ischemia
/
Drug Industry
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
J. Pak. Med. Assoc.
Year:
2005
Similar
MEDLINE
...
LILACS
LIS